To further investigate its role in carcinogenic progression, they developed a selective small-molecule inhibitor of RIPK1 and found that RIPK1 promotes differentiation of tolerogenic macrophages in the pancreatic cancer TME, leading to adaptive immune activation and tumor protection. This evidence concerns the gene RIPK1 and familial pancreatic carcinoma.